Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1968 2
1971 1
1972 5
1973 2
1974 4
1978 4
1980 4
1981 2
1982 4
1983 2
1984 6
1985 3
1986 4
1987 8
1988 8
1989 5
1990 8
1991 10
1992 13
1993 24
1994 14
1995 18
1996 20
1997 15
1998 8
1999 21
2000 26
2001 31
2002 20
2003 19
2004 19
2005 18
2006 25
2007 22
2008 17
2009 39
2010 27
2011 27
2012 23
2013 32
2014 38
2015 38
2016 36
2017 35
2018 29
2019 27
2020 35
2021 42
2022 34
2023 57
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

851 results

Results by year

Filters applied: . Clear all
Page 1
Hypertrophic cardiomyopathy: the future of treatment.
Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Tuohy CV, et al. Eur J Heart Fail. 2020 Feb;22(2):228-240. doi: 10.1002/ejhf.1715. Epub 2020 Jan 9. Eur J Heart Fail. 2020. PMID: 31919938 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility, and reduced compliance. It is the most common inherited monogenic cardiac conditi
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in l
Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Ismayl M, et al. Curr Probl Cardiol. 2023 Jan;48(1):101429. doi: 10.1016/j.cpcardiol.2022.101429. Epub 2022 Sep 24. Curr Probl Cardiol. 2023. PMID: 36167226 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unchanged for decades until the recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor. ...Compared to placebo, mavacamte
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unc
Cardiomyopathies: An Overview.
Ciarambino T, Menna G, Sansone G, Giordano M. Ciarambino T, et al. Int J Mol Sci. 2021 Jul 19;22(14):7722. doi: 10.3390/ijms22147722. Int J Mol Sci. 2021. PMID: 34299342 Free PMC article. Review.
The search keywords were "cardiomyopathies, sudden cardiac arrest, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy, arrhythmogenic cardiomyopathy (ARCV), takotsubo syndrome". RESULTS: Hypertrophic
The search keywords were "cardiomyopathies, sudden cardiac arrest, dilated cardiomyopathy (DCM), hypertrophic cardiomyopath
Hypertrophic cardiomyopathy: a systematic review.
Maron BJ. Maron BJ. JAMA. 2002 Mar 13;287(10):1308-20. doi: 10.1001/jama.287.10.1308. JAMA. 2002. PMID: 11886323 Review.
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic cardiac disease caused by a variety of mutations in genes encoding sarcomeric proteins and characterized by a …
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardio
Hypertrophic cardiomyopathy: part 1 - introduction, pathology and pathophysiology.
Varma PK, Neema PK. Varma PK, et al. Ann Card Anaesth. 2014 Apr-Jun;17(2):118-24. doi: 10.4103/0971-9784.129841. Ann Card Anaesth. 2014. PMID: 24732610 Review.
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease with many genotype and phenotype variations. Earlier terminologies, hypertrophic obstructive cardiomyopathy and idiopathic hypertrophic sub-aortic stenosis are n
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease with many genotype and phenotype variation
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Braunwald E, et al. Eur Heart J. 2023 Nov 21;44(44):4622-4633. doi: 10.1093/eurheartj/ehad637. Eur Heart J. 2023. PMID: 37804245 Free PMC article. Review.
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mav …
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatmen …
Applications of Gene Therapy in Cardiomyopathies.
Argiro A, Bui Q, Hong KN, Ammirati E, Olivotto I, Adler E. Argiro A, et al. JACC Heart Fail. 2024 Feb;12(2):248-260. doi: 10.1016/j.jchf.2023.09.015. Epub 2023 Oct 7. JACC Heart Fail. 2024. PMID: 37966402 Review.
Furthermore, promising results have been shown in animal models of gene therapy in hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy. This review summarizes the gene therapy techniques, the toxicity risk associated with adeno-associated virus deli …
Furthermore, promising results have been shown in animal models of gene therapy in hypertrophic cardiomyopathy and arrhythmoge …
Apical Hypertrophic Cardiomyopathy: The Variant Less Known.
Hughes RK, Knott KD, Malcolmson J, Augusto JB, Mohiddin SA, Kellman P, Moon JC, Captur G. Hughes RK, et al. J Am Heart Assoc. 2020 Mar 3;9(5):e015294. doi: 10.1161/JAHA.119.015294. Epub 2020 Feb 28. J Am Heart Assoc. 2020. PMID: 32106746 Free PMC article. Review. No abstract available.
Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Sebastian SA, Padda I, Lehr EJ, Johal G. Sebastian SA, et al. Am J Cardiovasc Drugs. 2023 Sep;23(5):519-532. doi: 10.1007/s40256-023-00599-0. Epub 2023 Aug 1. Am J Cardiovasc Drugs. 2023. PMID: 37526885 Review.
Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower left ventricular outflow tract (LVOT) gradients and improve heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). Based on the REDWOOD-HC …
Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower left ventricular outflow tract (LVOT) gradie …
Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.
Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, Lai A, Amr A, Haas J, Proctor T, Ehlermann P, Jensen K, Katus HA, Meder B. Sedaghat-Hamedani F, et al. Clin Res Cardiol. 2018 Jan;107(1):30-41. doi: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24. Clin Res Cardiol. 2018. PMID: 28840316 Review.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease, which goes along with increased risk for sudden cardiac death (SCD). ...The average frequency of mutations in MYBPC3 (20%) and MYH7 (14%) was higher than TNNT2 and TNNI3 …
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease, which goes along with increas …
851 results